SPRAVATO® Treatment
in Newark, NJ
A different approach to treatment-resistant depression (TRD).
Explore SPRAVATO® (esketamine) nasal spray, an FDA-approved treatment optionfor adults who haven’t experienced adequate relief from traditional antidepressant medications.
If you’ve tried 2 or more antidepressants, and they haven’t worked well for you, you may have treatment-resistant depression.
If you’re one of the 21 million adults suffering from clinical depression and struggling to manage your symptoms, you’re not alone.
According to a study, 1 in 3 people didn’t experience improvement in depressive symptoms when taking antidepressants alone.
UNDERSTANDING SPRAVATO®
What is SPRAVATO®?
SPRAVATO® (esketamine) is an FDA-approved prescription nasal spray used to treat treatment-resistant depression (TRD) in adults.
SPRAVATO® may be prescribed either as monotherapy or alongside an oral antidepressant. It is also approved, when used with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions.
Unlike traditional antidepressants, SPRAVATO® affects the brain’s glutamate system, although its exact antidepressant mechanism is not fully understood. Treatment is self-administered under medical supervision at a certified treatment center.
SPRAVATO® is not approved for use in children. It is not known whether SPRAVATO® is effective in preventing suicide or reducing suicidal thoughts or actions.
Video courtesy of SPRAVATO® (esketamine) / Johnson & Johnson. For educational purposes only. SPRAVATO® is a prescription medication with serious risks and warnings.
IS SPRAVATO® RIGHT FOR YOU?
Who might benefit from SPRAVATO®?
For adults living with treatment-resistant depression, finding an effective treatment can be challenging. SPRAVATO® may be an option for certain patients who haven’t experienced adequate relief from previous antidepressant medications.
Adults with depression
SPRAVATO® may be an option for adults diagnosed with treatment-resistant depression (TRD).
Limited Previous Success
You have tried at least two different antidepressants without adequate improvement.
Supervised Treatment
SPRAVATO® is self-administered under medical supervision at a certified healthcare setting.
THE TREATMENT PROCESS
What to expect
during treatment
SPRAVATO® treatment takes place only in a certified healthcare setting under medical supervision. Before your appointment, there are a few important things to know:
Avoid eating for at least 2 hours and drinking liquids for at least 30 minutes before treatment.
If you need to use nasal corticosteroids or decongestants, take them at least 1 hour before SPRAVATO®.
Follow the dosage and treatment schedule provided by your healthcare professional.
*Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep.
Supervised administration
You will administer SPRAVATO® nasal spray yourself
under the supervision of a healthcare provider.
Post-treatment monitoring
Medical supervision for at least two hours while a healthcare professional monitors for potential side effects, such as increased blood pressure, dissociation, and sedation.
Confirmation & discharge
Once you are clinically stable, you may leave the treatment center with transportation arranged in advance.*
Watch how treatment works
Get a closer look at the SPRAVATO® treatment experience.
This video walks through your first appointment through ongoing treatments. Understand what happens during sessions, how monitoring works, and how you and your healthcare team track progress.
IMPORTANT SAFETY INFORMATION
You should know
Before beginning SPRAVATO®, your healthcare provider will review your medical history, current medications, and overall health to determine whether treatment is appropriate for you. Understanding the potential risks and necessary precautions is an important part of making an informed decision.
Important considerations
- SPRAVATO® is not recommended during pregnancy or breastfeeding
- Patients with certain vascular conditions or a history of intracranial hemorrhage may not be eligible.
- Blood pressure is assessed before and after each treatment.
- Ongoing collaboration with your prescribing provider and care team is essential.
Potential risks
- Sedation and dissociation
- Respiratory depression
- Increased blood pressure
- Risk of abuse or misuse
Because of the risks for sedation, dissociation, respiratory depression, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program.
North Ward Behavioral Health Center (NWBHC) is a certified SPRAVATO® treatment setting participating in the SPRAVATO® REMS program.
Please see Indications and Important Safety Information, full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.
HELPFUL VIDEOS
Learn more about SPRAVATO®
What is SPRAVATO® (esketamine)?
Learn what SPRAVATO® is and whether it may be an appropriate treatment option for you.
What is SPRAVATO® (esketamine)? *SPANISH*
Conozca qué es SPRAVATO® y descubra si puede ser una opción de tratamiento adecuada para usted. Traducido al español para su comodidad.
What is Treatment-Resistant Depression?
Learn what treatment-resistant depression (TRD) means, why it occurs, and how a treatment like SPRAVATO® (esketamine) may help.
How SPRAVATO® (esketamine) CIII Nasal Spray Works
Discover how SPRAVATO® (esketamine) CII Nasal Spray works as a different treatment option for adults with treatment-resistant depression (TRD).
SPRAVATO® (esketamine) Instructions for Use
Learn how to use SPRAVATO® (esketamine) before your visit.
Hear From Experts
Hear two psychiatrists answer frequently asked questions about SPRAVATO® (esketamine).
Amelia's Story: A SPRAVATO® Patient Experience
Meet Amelia: A real patient with treatment-resistant depression.
Ben's Story: A SPRAVATO® Patient Experience
Meet Ben: A real patient with treatment-resistant depression.
FREQUENTLY ASKED QUESTIONS
Let's answer some
common questions
Find answers to common questions about SPRAVATO® treatment, including who may be eligible, important safety considerations, potential side effects, and what to discuss with your healthcare provider before starting treatment.
Please see Indications and Important Safety Information, full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.
Do NOT take SPRAVATO® if any of the following applies to you:
You are allergic to esketamine, a similar medicine called ketamine used for anesthesia, or any of the other ingredients in SPRAVATO®.
You have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation) or a history of bleeding in the brain.
Be sure to tell your healthcare provider if you have heart, brain or liver problems; if you have psychosis; or if you are pregnant, planning to become pregnant, breastfeeding or planning to breastfeed. You should not take SPRAVATO® if you are pregnant. You should not breastfeed if you are taking SPRAVATO®.
Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
You cannot take SPRAVATO® on your own. You will administer SPRAVATO® nasal spray yourself under the supervision of a healthcare provider, at a certified SPRAVATO® treatment center.
You can choose the location that works best for you; ask your healthcare provider to help find a location. SPRAVATO® cannot be purchased at a pharmacy.
Because of the risks for sedation or loss of consciousness, dissociation, respiratory depression, and abuse and misuse, SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program.
Before you take SPRAVATO®, talk to your healthcare provider about your full medical and depression treatment history, including if you have a history of abusing prescription or street drugs, or a problem with alcohol.
Do not take SPRAVATO® if you have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation), a history of bleeding in the brain or if you are allergic to esketamine, ketamine or any of the ingredients in SPRAVATO®.
Be sure to tell your healthcare provider if you have heart, brain or liver problems; if you have psychosis; or if you are pregnant, planning to become pregnant, breastfeeding or planning to breastfeed. You should not take SPRAVATO® if you are pregnant. You should not breastfeed if you are taking SPRAVATO®.
Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
These are not all the conditions you should tell your healthcare provider about before starting SPRAVATO®. For a full list of conditions, please see the Medication Guide.
No, SPRAVATO® (esketamine) CIII nasal spray is a derivative of ketamine.
SPRAVATO® is an FDA-approved nasal spray for treatment-resistant depression; it is also approved to treat depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions.
Ketamine has not been approved by the FDA to treat depression. Both SPRAVATO® and ketamine are Schedule III controlled substances under the US Controlled Substances Act.
No, treatment with SPRAVATO® is not recommended during pregnancy or while breastfeeding. SPRAVATO® may harm your baby. You should let your healthcare provider know if you are pregnant, planning to become pregnant, breastfeeding or planning to breastfeed. If you are a woman planning to start SPRAVATO®, and are of childbearing age, you should use highly effective contraception while taking SPRAVATO®. Talk with your healthcare provider about methods of birth control that should be used.
If you become pregnant while being treated with SPRAVATO®, you should talk to your healthcare provider as soon as possible about discontinuing treatment and about other options for treating your depression.
There is a pregnancy registry for women who are exposed to SPRAVATO® during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO® and their baby. If you become pregnant during treatment with SPRAVATO®, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online.
Dissociation is the feeling of being disconnected from your body, feelings, thoughts, or space and time.
Not everyone who takes SPRAVATO® experiences dissociation. However, studies showed that 61%-84% of people taking SPRAVATO® experienced this side effect.
Dissociation is a side effect, not an indication of how it’s working.
Schedule an Appointment with
North Ward Behavioral Health
Center
Just as you would visit a primary care facility to address issues with your physical health, you need to visit a mental health specialist when you need help.
The services offered by North Ward Behavioral Health Center take great pride in the level of care we provide our clients every day. To learn more about our services or the additional facilities within our network, please don’t hesitate to reach out.
Make an appointment with North Ward Behavioral Health Center of Newark, NJ, for more information today.
- 508-510 Mount Prospect Avenue Newark, NJ, 07104
- (862) 229-1515
- E-FAX: 888-412-1759
- helpme@nirvanahealthcare.com